Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Acute Promyelocytic Leukemia
Interventions
DRUG

Tamibarotene

Self-administered tablets BID (approximately one hour after breakfast \& dinner) during each 6 week cycle

DRUG

Arsenic trioxide

Administered intravenously Monday thru Friday at 0.15 mg/kg - 30 doses per cycle.

Trial Locations (1)

60611

Northwestern University, Chicago

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

CytRx

INDUSTRY

collaborator

Cephalon

INDUSTRY

lead

Northwestern University

OTHER

NCT00985530 - Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia | Biotech Hunter | Biotech Hunter